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Laboratory Survey of Fluoroquinolone Activity
Francis Bellido and Jean-Claude Pechere From the Department of Microbiology, Centre Medical
Universitaire, Geneva, Switzerland
Fluoroquinolones are active against a wide variety of bacteria. The antibacterial spectra
of fluoroquinolones encompass staphylococci, Bacillus species, and Corynebacterium spe-
cies implicated in infections of the immunocompromised host; Enterobacteriaceae; most
intestinal pathogens; and many gram-negative organisms commonly causing nosocomial
infections. Haemophilus influenzae, Haemophilus ducreyi, Neisseria gonorrhoeae, Neis-
seria meningitidis, and Branhamella catarrhalisare highly susceptible to this class of drugs.
Because of their ability to penetrate into phagocytes, fluoroquinolones have been tested
against intracellular pathogens: Legionella species, Rickettsia conorii, Rickettsia rickett-
sii, and Brucella melitensis are very sensitive; Chlamydia trachomatis and the mycoplasmas
are borderline; and some antimycobacterial activities deserve further investigation. Spe-
cies that are generally resistant include Pseudomonas maltophilia, Pseudomonas cepa-
cia, Pseudomonas pseudomallei, Alcaligenes species, Nocardia species, Bordetella bron-
chiseptica, and most anaerobes.
All quinolones are structurally related to nalidixic
acid, but the new generations of these drugs have
an antimicrobial potential that is substantially en-
hanced in comparison with that of the parent com-
pounds. Here we review the antibacterial spectrum
of the newer quinolones as it has been described in
the literature issued since the First International Sym-
posium on New Quinolones in July 1986. Data on
MIC 90 values for the fluoroquinolones are summa-
rized in table 1.
Gram-Positive Cocci
Fluoroquinolones are generally active against sta-
phylococci, and there is no cross-resistance with
other groups of antibiotics. This activity encom-
passes both methicillin-susceptible and methicillin-
resistant strains of Staphylococcus aureus [1-6],
Staphylococcus epidermidis [1,6, 7], Staphylococ-
cus haemolyticus [1, 7], Staphylococcus hominis, and
Staphylococcus saprophyticus. Ciprofloxacin [8, 9]
and enoxacin [10] have been found to be as effica-
cious as vancomycin for the treatment of experimen-
tal endocarditis caused by methicillin-resistant
S. aureus. However, resistance can emerge during
therapy for staphylococcal infection with a fluoro-
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quinolone, as has clearly been shown in a smiliar
model Ill]. Fluoroquinolones express weaker activ-
ity against streptococci, whatever the species con-
sidered [4, 5, 12-14]; this observation has been con-
firmed in experimental enterococcal endocarditis,
which was less effectively treated with ciprofloxacin
than with procaine penicillin [15]. MIC90 values for
commonly used fluoroquinolones against strep-
tococci are typically ~I mg/L, but newer compounds
such as A-61827 have shown improved antistrep-
tococcal activity [16]
Gram-Positive Bacilli
Fluoroquinolones have been tested against various
difficult-to-treat gram-positive bacilli that are in-
creasingly implicated in severe infections of the
immunocompromised host. In tests with Listeria
monocytogenes, MIC 90 values exceed the cutoff
point for susceptibility to fluoroquinolones in most
cases, but there are notable exceptions with ciproflox-
acin and ofloxacin [4, 5, 17]. More potent activities
have been reported against Corynebacterium species
[18], including strains of group D2 [19, 20] and group
JK [17,21].Bacillus species [17,22], and notably the
pathogenic Bacillus cereus [22], are within the spec-
trum of activity of ciprofloxacin.
Activity against Nocardia asteroides varies widely
from strain to strain [4, 23, 24]. Although most iso-
lates seem inaccessible to the fluoroquinolones, oc-
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Table 1. In vitro activity of three quinolones as reported in the recent literature (July 1986 through July 1988).
Reported range of MIC.o values (mg/L)
Organism Cpfx Ofx Pfx Reference(s)
Acinetobacter species 0.06-1 1 1 4, 5, 37,49
Aeromonas hydrophila 0.008-0.06 0.015 0.06 5, 53
Agrobacterium species 0.06 0.5 0.25 5
Alcaligenes species 2-16 4-32 8-32 5, 37, 58
Bacillus species 0.2-1 17,22
Bacteroides species 4->64 4-64 >64 25, 59-62
Bordetella bronchiseptica 0.5-4 8 2 35, 37
Bordetella parapertussis <0.06 0.12-0.25 35
Bordetella pertussis 0.12 0.5 35, 36
Branhamella catarrhalis 0.015-0.03 0.25 4,34
Brucella melitensis 0.5-0.8 0.8 6 84, 85
Campylobacter jejuni/coli 0.25-1 0.25-2 2 5,6,42
Capnocytophaga species 0.06-0.12 0.25-0.5 0.5 54, 55
Chlamydia trachomatis 1-1.56 1.56 76-80
Citrobacter diversus 0.03-0.06 4,44,49
Citrobacter freundii 0.015-0.25 0.25 4,5,44,49
Clostridium species 1-8 8->64 59,60
Corynebacterium, group D2 1 0.25-0.5 3, 19, 20
Corynebacterium, group JK 1-16 17, 21
Enterobacter cloacae 0.06-0.12 0.25 4,6,49
Enterobacter species 0.03-0.12 0.5 1 4,5,49
Escherichia coli 0.03-0.6 0.06 0.125-0.25 4, 5, 25, 49
Fusobacterium species 8-16 >64 25
Gardnerella vaginalis 4 32 25,80
Haemophilus ducreyi <0.06 <0.06 25,29
Haemophilus influenzae 0.008-0.03 0.015-0.03 0.03 4-6, 30
Klebsiella pneumoniae 0.06-0.24 0.25 3,4,49
Klebsiella species 0.06-0.12 0.25 0.5 3,45,49
Legionella species 0.125 0.06 72
Listeria monocytogenes 0.5-3 2 8 4,5, 17
Mobiluncus species 4 32 25
Moraxella species 0.5 2 37
Morganella morganii 0.03 0.125-0.25 0.5 4, 5, 6, 49
Mycobacterium avium complex 2-50 8-50 63, 64, 66-69
Mycobacterium chelonae 4-25 100 64,70
Mycobacterium fortuitum 0.25 0.4 64,70
Mycobacterium kansasii 2 2-3 64,67
Mycobacterium marinum 0.8-2 6 64,70
Mycobacterium scrofulaceum >8 25 64,70
Mycobacterium tuberculosis 0.5-1 0.8-1 63-67, 70
Mycobacterium ulcerans 0.5 64
Mycoplasma species 1-8 80, 81
Neisseria gonorrhoeae 0.002-0.03 0.015-0.03 6, 26, 28
Neisseria meningitidis 0.004 0.015 0.03 4,5
Nocardia asteroides 8 16-64 64 5,23
Peptococcus species 4-8 16 60,61
Plesiomonas shigelloides 0.008 0.015 0.06 5
Propionibacterium species 4-64 4 60
Proteus mirabilis 0.12 0.25 3,4,49
Proteus species (indole-positive) 0.03-0.06 0.25-2 0.25 3-6,49
Providencia species 0.06-8 1 0.25 4,5
Pseudomonas aeruginosa 0.25-2 2 2-4 4-6, 21, 37, 48, 49
Pseudomonas cepacia 2-4 16 8 4,6,37
Pseudomonas fluorescens 0.25-1 8 4 4, 6, 37, 48
Pseudomonas maltophilia 1-16 4-8 2-4 4, 5, 37, 48, 49, 51
Pseudomonas pseudomallei 8 8-32 6,52
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Table 1. (continued)
Reported range of MIC.o values (mg/L)
Organism Cpfx Ofx Pfx Reference(s)
Pseudomonas putida 0.25-4 8 6,48
Pseudomonas stutzeri 0.5 I 37
Salmonella species <0.015-0.25 <0.06 0.25 4-6
Serratia marcescens 0.125-1 0.25-2 I 4-6,49
Shigella species <0.015-0.03 0.06-0.12 0.06-0.12 4-6, 39
Staphylococcus aureus (methicillin-sensitive) 0.4-1 0.5-2 0.5-1 I, 4-6, 17, 49
S. aureus (methicillin-resistant) 0.25-1 0.4->16 0.5-1 I, 2, 4-6, 17, 49
Staphylococcus epidermidis 0.25-1 0.25-0.5 I 1,4-7
Staphylococcus haemolyticus 0.5-1 0.5 0.5 1,4, 7
Staphylococcus hominis I 0.5 I I, 4
Staphylococcus saprophyticus 0.5-1 I 4 1,4, 5
Streptococcus faecalis 0.5-2 2 4 4, 5, 14,49
Streptococcus mitis 2 4
Streptococcus pneumoniae I 8 4, 5
Streptococcus salivarius 2 4
Streptococcus sanguis 0.25 4
Streptococcus species, group A 2 4
Streptococcus species, group B 0.5-4 16 4, 5, 12
Streptococcus species, group C 2 4
Streptococcus species, group G 1-2 4, 12, 13
Ureaplasma urealyticum 4-8 80, 81
Vibrio parahaemolyticus 0.06 0.5 6
Yersinia enterocolitica 0.03 <0.06-0.12 0.25 4-6
casional strains appear to be susceptible in vitro to
ciprofloxacin [5, 23], ofloxacin [5, 23], pefloxacin
[5], and/or enoxacin [24].
Gram-Negative Genital Pathogens
FIuoroquinolones show extremely potent activity
against Neisseria gonorrhoeae [25-28] and Hae-
mophilus ducreyi [25, 29], with no cross-resistance
to other groups of antibiotics, notably the penicil-
lins. In contrast, Mobiluncus species are always resis-
tant [25], and Gardnerella vaginalisdoes not appear
susceptible in most cases [25].
Gram-Negative Respiratory Pathogens
Fluoroquinolones are potent inhibitors of Hae-
mophilus influenzae [4-6], including 13-lactamase-
producing strains [6, 30], 13-lactam-tolerant strains
[30), and multiresistant isolates [31]. In murine pneu-
monia caused by H. influenzae, ciprofloxacin [32],
enoxacin [33], and ofloxacin [33] produced more in-
trapulmonary killing than did ampicillin. Branham-
ella catarrhalis is also highly susceptible to newer
quinolones [4, 34], and this susceptibility is indepen-
dent of 13-lactamaseproduction [34]. With regard to
Bordetella species, Bordetella pertussis is most sus-
ceptible [35, 36]; MICgo values are two- to fourfold
higher against Bordetella parapertussis [35]; and
most strains of Bordetella bronchiseptica are resis-
tant [35, 37].
Gram-Negative Intestinal Pathogens
Potent activities against aerobic or microaerophilic
enteropathogens have been reported. Besides the
well-recognized activity against Escherichia coli [38],
multiresistant Shigella species have been consistently
susceptible to f1uoroquinolones [39]. The antibac-
terial spectrum of f1uoroquinolones also encom-
passes Yersinia enterocolitica [4-6, 38], Aeromonas
hydrophila [5, 38], Plesiomonas shigelloides [5, 38],
Vibrio parahaemolyticus [6], and most Salmonella
species [4, 5] (including ampiciIIin- and chloram-
phenicol-resistant strains [6]). Ciprofloxacin consis-
tently cured lethal Salmonella typhimurium infec-
tion in immunocompromised mice, whereas
ampicillin or chloramphenicol did not [40). Higher
MICgo values have been shown against Campylobac-
ter jejuni, Campylobacter coli [5, 38, 41, 42], and
Campylobacter pylori [43]. A majority of these
strains can be considered susceptible, but occasional
resistance has been encountered.
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Gram-Negative Nosocomial Organisms
Most nosocomial Enterobacteriaceae - notably
Klebsiella species, Enterobacter species, Citrobac-
ter species, Providencia species, Proteus species,
Morganella morganii, and Serratia marcescens-are
inhibited by readily achievable fluoroquinolone con-
centrations [4-6, 44]. This susceptibility is seen in
organisms that are resistant to penicillins, cephalo-
sporins, and aminoglycosides. There are clear excep-
tions among these strains, however, [5,45,46], and
resistance may become an increasing concern in the
future if fluoroquinolones are widely used in hospi-
tal practice.
For Pseudomonasaeruginosa [4-6, 47-49], MIC90
values are generally higher than those for Enterobac-
teriaceae; the activity of compounds such as nor-
floxacin is too weak for clinical use except in urinary
tract infections. Ciprofloxacin, which is the most ef-
fectivequinolone against P.aeruginosa, generally ex-
hibits MICs within the susceptible range, but resis-
tance can occur during therapy, as has been shown
in a murine model [50]. With regard to other Pseu-
domonas species, the activity of fluoroquinolones
is variable. MIC9 0 values for Pseudomonas
fluorescensand Pseudomonasstutzeri [48]are simi-
lar to those for P. aeruginosa, while Pseudomonas
maltophiliaand Pseudomonascepacia [4, 48, 51] are
more resistant. A non-nosocomial Pseudomonas
species, Pseudomonas pseudomallei (which is re-
sponsible for melioidosis), should be considered
resistant [52].
Fluoroquinolones are highly active against Aero-
monas hydrophila [5, 38, 53], Plesiomonas shigel-
loides [5, 38], Capnocytophaga species [54, 55],
Agrobacterium species [5], and dysgonic fermenter
2 [56]. Higher MIC90 values (but still below the cutoff
point for susceptibility) have been reported for a
majority ofAcinetobacterspecies [5,46,49,57]. Al-
caligenes denitrificans [5, 58] should be regarded as
resistant.
Strict Anaerobic Bacteria
Most clinically important anaerobes, such as Bac-
teroidesfragilis or Clostridium species are resistant
to presently marketed fluoroquinolones [25, 59-62].
Although ciprofloxacin is active in vitro against some
anaerobes (e.g.,Bacteroides ureolyticus and some an-
aerobic cocci), this activity is too aleatory for the
empiric treatment or the prophylaxis of anaerobic
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infections [59]. Newer, apparently more potent anti-
anaerobe compounds, such as A-61827 [16], may be
proven more effective in the future.
Special Intracellular Bacteria
Therapy for infections caused by intracellular bac-
teria is often difficult because the pathogens in situ
cannot be properly inhibited by the intracellular con-
centrations actually achieved by the most potent an-
tibiotics. Hence treatment schedules are prolonged,
adverse reactions are aggravated, and drug resistance
emerges easily. Since the fluoroquinolones are known
to be taken up by the host's phagocytic cells, their
potential uses for the treatment of intracellular in-
fections have aroused much interest. For Myco-
bacterium hominis, MIC 90 values of ciprofloxacin
[63-66], ofloxacin [65-67], and fleroxacin [64] were
found to be significantly lower than the peak serum
levels produced by these agents. In the case of
ciprofloxacin and ofloxacin, synergistic effects with
rifampin and isoniazid were demonstrated [65].
Clearly, these in vitro findings deserve further clini-
cal studies. MICs for the Mycobacterium avium
complex [63,64, 66-69], Mycobacterium xenopi [64],
Mycobacterium scrojulaceum [64, 70], and Myco-
bacterium chelonae [64, 70] are higher and proba-
bly not achievable by therapy, but other potentially
susceptible atypical mycobacteria may include
Mycobacterium kansasii, Mycobacterium fortuitum,
Mycobacterium ulcerans, and Mycobacteriummar-
inum [64,69, 70]. Fluoroquinolones have also been
tested against Mycobacterium leprae by measure-
ment of intracellular ATP decay after direct in vitro
exposure to antimicrobial agents [71]. In this system,
ciprofloxacin showed some activity -lower than that
exhibited by conventional antileprosy drugs,
however.
Legionellosis represents a potential target for
fluoroquinolones. In vitro all species of Legionella
have been highly susceptible to ciprofloxacin, oflox-
acin, enoxacin, and norfloxacin [72]. In a system
using peripheral human monocytes, fluoroquino-
lones inhibited the growth of intracellular Legionella
pneumophila at concentrations readily achievable in
serum [73]. In experimental legionellosis, ciproflox-
acin [72, 74] or pefloxacin [75] performed similarly
to or better than the reference antibiotic, erythro-
mycin or rifampin. Further clinical studies are now
in progress.
Mode of Action: Antibacterial Activity
Against Chlamydia trachomatis, ciprofloxacin
[76-80], ofloxacin [77, 78], fleroxacin [78], lomeflox-
acin [78], and other investigational quinolones [78,
80] have shown inhibitory activity at concentrations
attainable in serum. The standard drugs tetracycline
and erythromycin, however, are more active on a
weight-for-weight basis, and the actual role of quino-
lones in therapy for chlamydial infections has yet to
be determined. Newly developed quinolones such as
T-3262 [78] display an especially low MIC90 against
C. trachomatis and may deserve special considera-
tion in further clinical investigations.
Several quinolones, including ciprofloxacin, ex-
hibit some activity against Mycoplasma hominis,
Mycoplasma pneumoniae, and Ureaplasma urealyti-
cum [79-81]. These observations also require clini-
cal evaluation.
Twostudies suggest that ciprofloxacin and peflox-
acin may be useful in rickettsiosis. These compounds
were effective in vitro and in ovo against Rickettsia
conorii and Rickettsia rickettsii [82, 83]. Ciproflox-
acin, ofloxacin, and pefloxacin were also active
against Brucella melitensis [84, 85].
New Fluoroquinolone Compounds
More recently developed compounds, such as flerox-
acin [86-88], difloxacin [89-91], A-56220 [89-91],
and lomefloxacin [92], display the typical features
of the antibacterial activity of previous fluoroquino-
lones. Other compounds, notably T-3262 [93], CI-
934 [94],S-25930[95], S-25932[95],E-3846 [96], and
temafloxacin [97, 98], show somewhat improved ac-
tivity against gram-positive organisms (including
S. aureus). PO 127,391 exhibits more potent activ-
ity against C. trachomatis or anaerobes [99].
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